Highlights

  • AML3D (ASX:AL3) reported FY26 revenue, including Lease income, of AUD 12.5 million, up 70% year on year.
  • The company recorded second-half FY26 EBITDA of AUD 608,000 after expanding its industrial and defence activity.
  • Contracted work carried into FY27 amounted to AUD 16.8 million, compared with AUD 9 million a year earlier.
  • Cash at 30 June 2026 was approximately AUD 26.7 million, supporting announced US and UK Investment plans.

AML3D (ASX:AL3) develops industrial metal additive Manufacturing systems and components using its ARCEMY wire-arc printing technology. On 20 November 2026, shares were quoted at AUD 0.098, down 2.00% on that date. Recent 2026 company disclosures cover developments in the Business and provide the context for assessing its reported operations, financial position and near-term milestones.

US Navy Supply-Chain Equipment Deliveries

AML3D’s FY26 results highlighted deployment of ARCEMY equipment and component manufacturing activity in the United States. The company reported contracts to deploy 14 systems into the US Navy Supply chain and two additional systems for industrial manufacturing applications. It also described a AUD 2.6 million order for replacement components used in US Navy submarines. Equipment orders and recurring component work have different delivery and Revenue profiles. The order history indicates contracted activity, but individual delivery timing still determines when the associated revenue is recognised.

Revenue Growth and Second-Half Profitability

Revenue including lease income rose 70% year on year to AUD 12.5 million in FY26. AML3D reported AUD 608,000 of EBITDA for the second half, representing its first EBITDA-profitable half-year. Confirmed orders reached a peak of AUD 29 million during FY26, while AUD 16.8 million in contracted work was carried into FY27. The company also disclosed an estimated global sales pipeline of AUD 78 million at year-end. A pipeline is a management estimate of potential business, not an executed order book, and should not be presented as guaranteed sales.

Capacity Expansion Beyond the United States

At 30 June 2026, AML3D reported cash of approximately AUD 26.7 million. Its expansion program included a planned AUD 12 million investment to increase US capacity and a proposed AUD 5 million UK technology centre. The company also reported activity involving UK defence feasibility work and distribution arrangements. Capital spending precedes any certainty about manufacturing utilisation or future earnings. The Balance Sheet therefore supports the ability to pursue these plans, while subsequent reporting must demonstrate the pace of commissioning and realised customer demand.

Risks and Uncertainties to Watch

Defence procurement involves qualification, delivery schedules and customer acceptance requirements. Production scaling may introduce equipment installation, engineering and workforce challenges. Contracted work can move between reporting periods depending on completion milestones and accounting recognition. The AUD 78 million sales pipeline is not equivalent to contracted revenue. Overseas capacity expansion also creates execution and foreign-exchange exposure. These matters are commercial risks and should not be framed as established delivery failures.

What to Watch Next

The FY27 order carryover provides an identifiable base for tracking project execution. Investors can monitor commissioning of additional US manufacturing capacity and progress towards the planned UK centre. New ARCEMY systems, component orders and acceptance milestones may help explain revenue recognition. Reporting should also separate capital spending, operating cash flows and the evolution of the confirmed order book. Further profit measures will indicate whether the second-half FY26 EBITDA result develops into a sustained pattern.

Key Insights

AML3D has reported distinct 2026 developments across its operations and financial position. The near-term assessment depends on the specific measures and milestones described above, rather than an assumed relationship between share trading and company announcements. Subsequent official disclosures will clarify which plans were implemented and how the financial results changed.